In Stock
Sacubitril + Valsartan Tablets
Sacubitril + Valsartan Tablets 49mg + 51mg | Cardiac / Hypertension
- Product Form: Raw Powder / API
- Not for direct consumer use
- For qualified buyers, formulation, compounding, R&D, and regulated business use only
- COA/MSDS available upon request
- Final sale depends on buyer country import regulations
Disclaimer: Products listed on this website are intended for qualified business buyers, research, formulation, compounding, or regulated pharmaceutical use only. Products are not intended for direct consumer use. Import permission, registration, customs clearance, and local regulatory compliance are the responsibility of the buyer in their respective country.
Description
This document provides a concise, practical summary of the generic combination medicine Sacubitril (49 mg) + Valsartan (51 mg). The information below covers product introduction, therapeutic uses, benefits, common side effects, safety advice, mechanism of action, dosing and administration guidance, quick practical tips, and known drug interactions. This material is intended for general informational purposes and does not replace professional medical advice.
Product Introduction
The combination of Sacubitril and Valsartan is used primarily for the long-term management of certain types of heart failure. Sacubitril is a neprilysin inhibitor that increases levels of beneficial peptides, and valsartan is an angiotensin II receptor blocker (ARB) that reduces the effects of the renin–angiotensin–aldosterone system. Together they reduce cardiac stress, improve cardiac function, lower blood pressure, and have been shown to reduce hospitalizations and mortality in appropriately selected patients with chronic heart failure with reduced ejection fraction (HFrEF).
Uses
-
Treatment of chronic heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and heart failure hospitalization.
-
Alternative to ACE inhibitor or ARB therapy in eligible patients with symptomatic heart failure who remain symptomatic despite optimized therapy.
-
Management of hypertension is an additional effect, though this combination is primarily indicated for heart failure therapy.
Benefits
-
Reduced risk of cardiovascular death in patients with HFrEF compared with some standard therapies.
-
Lower rate of hospitalization for heart failure due to improved cardiac unloading and neurohormonal modulation.
-
Improved symptoms and exercise tolerance for many patients when used as part of guideline-directed medical therapy.
-
Blood-pressure lowering effect that may benefit patients with concurrent hypertension.
Side Effects
Common side effects (may occur in some patients):
-
Low blood pressure (hypotension) — lightheadedness, dizziness.
-
Elevated blood potassium (hyperkalaemia) — may be detected on blood tests; severe cases can cause muscle weakness or irregular heartbeat.
-
Renal function changes — increases in serum creatinine may occur.
-
Cough and dizziness (less frequent than with ACE inhibitors for cough).
-
Angioedema (rare but potentially serious) — swelling of face, lips, tongue, or throat; requires immediate medical attention.
Less common but serious adverse effects should be reported immediately. If you experience severe dizziness, fainting, signs of allergic reaction or progressive shortness of breath, seek urgent medical care.
Safety Advice
-
Prescription only: Use this medicine only under the guidance of a physician experienced in heart-failure management.
-
Contraindications: Do not use concurrently with an ACE inhibitor or within 36 hours of the last ACE inhibitor dose because of increased risk of angioedema.
-
History of angioedema: Avoid use if there is a prior history of angioedema related to ACE inhibitors, ARBs, or neprilysin inhibitors unless a clinician determines benefits outweigh risks.
-
Pregnancy and breastfeeding: Not recommended in pregnancy (can cause fetal harm). Women of childbearing potential should use contraception. Discuss breastfeeding with a clinician — components may pass into breast milk.
-
Monitor blood pressure, renal function (serum creatinine), and serum potassium periodically, especially after initiation or dose changes.
-
Elderly patients may be more sensitive to blood-pressure lowering effects; start with caution and monitor closely.
How It Works
The combination pairs two complementary mechanisms:
-
Sacubitril: a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides and other vasoactive peptides. By inhibiting neprilysin, sacubitril increases levels of these peptides, which promote vasodilation, natriuresis (excretion of sodium), diuresis, and decreased sympathetic tone — all beneficial for heart-failure physiology.
-
Valsartan: an angiotensin II receptor blocker (ARB). It blocks the angiotensin II type 1 receptor, reducing vasoconstriction, aldosterone release, sodium and water retention, and adverse cardiac remodeling.
-
Combining the two yields greater neurohormonal modulation than an ARB alone, improving outcomes in selected HFrEF patients.
How to Use
Follow the prescribing clinician’s directions. Typical practical guidance includes:
-
Dosing: The product strength here (sacubitril 49 mg / valsartan 51 mg) corresponds to a combined 100 mg tablet. The exact starting dose depends on prior therapy, blood pressure, renal function, and tolerability. Some patients start at a lower dose and titrate up at intervals recommended by the prescriber.
-
Administration: Take by mouth, with or without food, usually twice daily if prescribed as the standard regimen. Maintain consistent timing each day.
-
Switching from ACE inhibitors: Allow a 36-hour washout period after stopping an ACE inhibitor before starting this combination.
-
Monitoring: Check blood pressure, kidney function, and potassium within 1–2 weeks of initiation or dose changes, then periodically as advised by your doctor.
-
Missed dose: If a dose is missed, take it as soon as remembered if enough time remains before the next dose. Do not double doses to make up for missed ones. Confirm specific instructions with your prescriber.
Quick Tips
-
Keep a blood-pressure log during the first weeks of therapy to share with your healthcare team.
-
Stay hydrated but report significant drops in blood pressure, lightheadedness, or fainting.
-
Avoid sudden standing from sitting or lying down to reduce dizziness from low blood pressure.
-
Carry a list of current medications to check for interactions (see next section).
-
Inform your clinician about any history of allergic reactions, kidney disease, or high potassium.
Drug Interactions
Important potential drug interactions to be aware of:
-
ACE inhibitors: Concurrent use or insufficient washout (less than 36 hours after stopping an ACE inhibitor) significantly increases the risk of angioedema.
-
Potassium-sparing agents and potassium supplements: (e.g., spironolactone, eplerenone, amiloride, triamterene) and potassium salts can raise serum potassium and increase hyperkalaemia risk when used together.
-
Other RAAS blockers: Combining with other ARBs or aliskiren (especially in patients with diabetes or renal impairment) can increase renal impairment, hypotension, and hyperkalaemia risk; generally not recommended.
-
Nonsteroidal anti-inflammatory drugs (NSAIDs): May reduce antihypertensive effect and, when combined with RAAS blockade, increase the risk of renal impairment and hyperkalaemia.
-
Diuretics: Concomitant use may increase hypotension risk when initiating therapy; monitor blood pressure and renal function.
-
Lithium: Co-administration with ARBs has been associated with lithium toxicity; monitor lithium levels closely if combined.
-
Drugs that affect renal function or potassium: Many drugs (e.g., trimethoprim, heparin, certain immunosuppressants) can affect potassium or kidney function and may interact clinically.
This list is not exhaustive. Always review new or over-the-counter medicines, herbal supplements, and topical preparations with a clinician or pharmacist before use.
When to Contact a Healthcare Provider
-
Symptoms of angioedema: swelling of face, lips, tongue, throat, or difficulty breathing.
-
Severe dizziness, fainting, or persistent lightheadedness.
-
Marked decrease in urine output, sudden swelling (edema), or a rapid rise in weight.
-
Severe or persistent cough, chest pain, or palpitations.
-
Any signs of electrolyte imbalance (muscle weakness, irregular heartbeat) or concerns after lab results.
Final Notes
Use this combination only under medical supervision. Individual treatment decisions, dosing, and monitoring must be guided by a healthcare professional who can assess the patient’s overall clinical status, co-morbidities, and concomitant medications.
If you would like this information placed into a downloadable Word document (.docx) arranged with a title page, table of contents, and section headers for printing or sharing, tell me if you want any additional items included (laboratory monitoring schedule, sample prescription wording, patient counseling checklist) and I will generate the file.
| Product Name | Sacubitril + Valsartan Tablets |
| Category | All Medicines, Cardiac / Hypertension |
| Form | Raw Powder |
| Grade | As per available specification |
| Documents | COA, MSDS, Invoice, Packing List |
| Packing | As per order quantity |
| MOQ | On request |
| Shipment | Air cargo / courier / buyer-approved route |
| Use | B2B, formulation, compounding, research & qualified buyer supply |
| Disclaimer | Subject to buyer country regulations |
Additional information
| Strength | 49mg + 51mg |
|---|
Customer Reviews
Only logged in customers who have purchased this product may leave a review.
